Combined Contraceptive Vaginal Ring or Norethisterone for Treatment of Idiopathic Menorrhagia
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 95
- 试验地点
- 1
- 主要终点
- Reduction in menstrual blood loss at the end of study (cycle 3) measured by pictorial blood loss assessment chart.
研究概览
简要总结
To compare the efficacy of a combined contraceptive vaginal ring (NuvaRing) and oral Norethisterone Acetate in treatment of Idiopathic heavy menstrual bleeding during fertile age
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 35 Years(Adult)
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Women with heavy menstrual bleeding based on PBAC score over 185 (mean of two control cycles)and desire contraception
排除标准
- •Menorrhagia of endocrine or systemic origin
- •other pathology e.g. patients with fibroids of any size, adenomyosis, endometriosis, pelvic inflammatory disease.
研究组 & 干预措施
NuvaRing
For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
干预措施: NuvaRing (Drug)
Norethisterone Acetate
Norethisterone Acetate tablets at a dose of 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
干预措施: Norethisterone Acetate tablets - 5mg (Drug)
结局指标
主要结局
Reduction in menstrual blood loss at the end of study (cycle 3) measured by pictorial blood loss assessment chart.
次要结局
- Haemoglobin and serum ferritin at the end of study (cycle 3)
